atorvastatin has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Baumert, TF; Chung, RT; Corey, KE; Hoshida, Y; Kim, MH; Kim, MY; Lee, Y; Qian, T; Sadreyev, RI; Salloum, S; Shroff, SG; Wong, LP; Xu, M | 1 |
| Nakayama, S; Snoeys, J; Sugiyama, Y; Toshimoto, K; Yamazaki, S | 1 |
| Chung, RT; Moriguchi, H; Sato, C | 1 |
3 other study(ies) available for atorvastatin and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted
| Article | Year |
|---|---|
Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Hepatitis C; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Proto-Oncogene Proteins c-akt | 2022 |
Physiologically-based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B.
Topics: Atorvastatin; Biomarkers; Cytochrome P-450 CYP3A; Drug Interactions; Hepatitis C; Humans; Models, Biological; Simeprevir | 2023 |
New translational research on novel drugs for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells.
Topics: Antiviral Agents; Atorvastatin; Hepacivirus; Hepatitis C; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Induced Pluripotent Stem Cells; Pyrroles; Quinolines | 2010 |